Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Clinical Benefit of 18F-Fluoroethyl-l-tyrosine(FET) PET/CT in Glioma Patients.

NCT07698457 is registered in ClinicalTrials.gov with Primo Biotechnology Co., Ltd as lead sponsor.

NCT NCT07698457
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07698457 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Clinical Benefit of 18F-Fluoroethyl-l-tyrosine(FET) PET/CT in Glioma Patients.
Lead sponsor
Primo Biotechnology Co., Ltd
Phase
Phase 3
Overall status
Not yet recruiting
Start date
October 1, 2026
Completion date
January 31, 2028
Enrollment
36 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

18f-fluoroethyl-l-tyrosine, glioma